substrates into bioactive small molecules that can act directly in the gastrointestinal tract or even 10 reach distant tissues following their absorption into general circulation (1-3). This fact, together with the tremendous inter-individual variation in gut microbial community structure and function (4) , highlights the need to design personalized diets for the prevention of human disease (5) . Yet, this ambitious goal has been difficult to obtain given the major gaps in our knowledge regarding the mechanism and scope of gut microbial metabolism. 15 Metabolism of lignans to enterolignans, which are one of the most commonly ingested sources of diet-derived phytoestrogens (6) , occurs exclusively via the action of gut-residing bacteria (7) . Lignans are ubiquitous in plants and consumed at estimated mean rates of 1-2 milligrams per day, 75% of which are the lignans pinoresinol (PINO) and lariciresinol (LAR) ( their activation by human gut bacterial enzymes (9, 10) . In rats, lignans tend to accumulate in cecal contents, a bacteria-dense region of the gut where significant bacterial metabolism of lignans may occur (11) . The downstream microbial metabolites, the phytoestrogens enterodiol (END) and enterolactone (ENL), have both structural and functional similarities to the endogenous hormone estrogen and broad impacts for host health and disease (9, 12) . Most notably, serum ENL levels are inversely associated with breast cancer risk in humans (13-16), and ENL dosed to rodent models of breast cancer decreases tumor burden (17, 18).
Despite the discovery of enterolignans in humans nearly 40 years ago, the enzymes 5 responsible for their production are unknown (19, 20) . Employing a bacterial consortium reported to mediate metabolism of dietary lignans (7, 21) , here, we used comparative genomics and transcriptional profiling (RNAseq) to link human gut bacterial genetic loci to all four types of chemical transformations involved in the conversion of dietarily abundant PINO and LAR to ENL.
The enzymatic activity for the initial two reactions (benzyl ether reductions) was validated by 10 heterologous expression. Together, these results provide new insights into the chemistry made possible by host-associated microbial communities; generalizable approaches to identify genes responsible for the gut microbial metabolism of dietary, therapeutic, or even endogenous small molecules; and an initial step towards the microbiome-based prediction of which individuals would benefit from a lignan-rich diet.
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The human gut microbiome metabolizes the dietary lignans PINO and LAR via four distinct types of chemical reactions-benzyl ether reduction, guaiacol demethylation, catechol dehydroxylation, and diol lactonization (Fig. 1A) (22)-each carried out by a different bacterial species to yield the final product ENL (7, 22, 23) . No single gut bacterium has been identified that can catalyze the diverse array of biotransformations constituting the lignan-metabolism pathway. 20 Instead, cooperation appears to be required among multiple species from distinct bacterial phyla to complete the full pathway. Four bacteria, each capable of performing one of the four types of chemistry converting lignans to enterolignans, were cultured under anaerobic conditions with each putative substrate. Consistent with prior studies (22, 24, 25) , Eggerthella lenta DSM 2243 was capable of catalyzing the first two reactions (Fig. 1B) , Blautia producta DSM 3507 metabolized SECO (Fig. 1C) , and Lactonifactor longoviformis DSM 17459 converted END to ENL (Fig. 1E) .
In contrast to prior reports (7, 22) , END was not detected following the incubation of dmSECO with E. lenta; instead, we identified two Gordonibacter species, close relatives of E. lenta, capable 5 of this reaction (Fig. 1D , Table S1 ). No significant growth defects were observed upon incubation of each bacterium with its respective substrate (500 µM in methanol).
Although the E. lenta type strain (DSM 2243) is capable of metabolizing PINO to SECO via benzyl ether reduction (Fig. 1B) , we were curious about whether this phenotype was found in other E. lenta strains. We recently reported the curation of 25 strains of the gut Actinobacterium 10 E. lenta and closely-related species of the Coriobacteriia class (26) . Using an HPLC-based assay, this panel of bacteria was screened for the metabolism of PINO to LAR and SECO (Fig. 2) .
Metabolism varied across strains; 9 strains (36%) did not produce any detectable metabolites (nonmetabolizers). Among the 16 metabolizers, the extent of metabolism varied considerably, from 4.8±0.5% to complete conversion of dosed PINO to the reduced products LAR and SECO (Table   15   S2 ). All of the metabolizing strains were from the Eggerthella genus, including 15 E. lenta strains and 1 E. sinensis strain.
Phylogenetic analysis revealed that the metabolizing strains were not monophyletic ( Table S3 ). This locus consisted of two genes predicted to encode a putative enzyme and a transcriptional regulator. The former has primary sequence homology to annotated fumarate reductases ( Fig. S2 ) and is referred to herein as benzyl ether reductase (ber). The latter, referred to herein as the ber regulator (berR), has primary sequence homology to annotated transcriptional regulators from the LuxR family. Consistent with its putative regulatory function (27) , berR is transcribed in reverse orientation to ber.
As E. lenta is presently a genetically intractable organism, we used heterologous 5 expression to confirm that Ber is sufficient to catalyze the benzyl ether reduction of PINO and LAR to SECO. Incubation of E. coli Rosetta 2(DE3) cells engineered to express Ber led to 97.2±1.9% conversion of PINO to the products LAR and SECO (Fig. 3A) . While there have been reports of genes from sphingomonads (bacteria commonly associated with plant roots) that enable conversion of PINO to LAR and SECO, these genes share no primary sequence homology with 10 ber (28). To our knowledge, the discovery of ber is the first report of a gut bacterial gene that encodes benzyl ether reduction.
While our comparative genomic approach has been valuable for learning about E. lenta, we currently have a limited set of strains for the remaining three bacterial species in the fourmembered PINO-to-ENL-metabolizing consortium. As an alternative approach, we turned to 15 transcriptional profiling (RNAseq) to search for genes that are up-regulated in response to each substrate-a strategy that we have successfully employed to implicate genes in the metabolism of pharmaceuticals (4, 29) .
Incubation of E. lenta DSM 2243 with PINO provided an additional validation for this
RNAseq-based approach to identify genes that encode xenobiotic-metabolizing activities. The 20 expression of four genes in E. lenta DSM 2243 was significantly altered (fold-change>|4|, FDR<0.01) upon exposure to PINO during exponential growth ( Fig. 3B ; Table S4 ). The ber gene was the most highly up-regulated by a factor of 500 [ber, 2670.9-fold; second most up-regulated gene (encoding a hypothetical protein), 5.4-fold]. The induction of ber transcription in response to PINO was confirmed by qRT-PCR on an independent set of cultures (Fig. 3C) . These results indicate that ber transcription is induced upon the cellular detection of Ber's substrate, PINO, and also suggest that RNAseq may be a general strategy to link genomic loci to specific dietary substrates. 5 Following the benzyl ether reductions of PINO that produce LAR and then SECO, lignan metabolism proceeds with Blautia producta DSM 3507 demethylating the 3-position methoxy groups of SECO, liberating two catechols to form didemethylsecoisolariciresinol (dmSECO) ( Table S5 ), as 10 determined by RNAseq. The most up-regulated gene (12.6-fold) exhibits sequence homology to known methyltransferases and is referred to herein as guaiacol lignan methyltransferase (glm), which putatively mediates demethylation of SECO to yield dmSECO (Fig. 4B, S2 ). Up-regulation of glm was validated by qRT-PCR (Fig. 4B) .
The bacterial lignan-metabolism pathway proceeds with Gordonibacter pamelaeae 3C 15 dehydroxylating the 4-position hydroxyl group in the catechol moiety of dmSECO, forming END (Fig. 1A, 1D) (22) . In search of the gene encoding the catechol lignan dehydroxlase (cld), RNAseq analysis of G. pamelaeae 3C exposed to dmSECO revealed a 19-gene cluster in which 15 genes were significantly up-regulated relative to vehicle (Fig. 4A , Table S6 ; fold-change>|4|, FDR<0.01). Two proteins encoded in this locus are chemically reasonable candidates for the 20 observed dehydroxylation (Fig. S2) . Conversion of END to phytoestrogenic ENL by Lactonifactor longoviformis DSM 17459, the final step in the lignan-bioactivation pathway (Fig. 1A, 1E ) (25), was investigated using RNAseq. L. longoviformis incubated with END revealed 6 genes that were up-regulated and 2 that were down-regulated in the presence of END relative to vehicle (Fig. 4A , Table S7 ; fold-10 change>|4|, FDR<0.01). Among these genes was a single genomic locus of three genes that exhibited transcript levels >300-fold higher in the presence of END (Fig. 4A, 4D) ; the second most (Table S8 ) (32). We developed a novel culture-independent, PCR-based assay for the presence/absence of each gene from community DNA extracted from stool samples (Supplementary Methods). The individual genes varied in their prevalence: ber, 93%; glm, 87%; cld2, 81%; edl1, 96%; and edl2, 99% (Fig. 5) . We did not detect any significant correlations between age, ethnicity, or body mass index and the presence of these genes. Remarkably, we detected the complete bacterial pathway for lignan metabolism in the majority (67.6%) of individuals, suggesting that this is a common mechanism by which the gut microbiome produces 5 phytoestrogenic enterolignans.
While bacterial species that participate in the multi-step, multi-organism metabolism of dietary lignans had previously been reported (22), our results demonstrate that strain-level genetic variation within the E. lenta population precludes prediction of lignan-metabolizing ability from a species-level depiction of the microbiome. This strain-level variation can be leveraged through the 10 use of comparative genomics to identify genetic determinants of lignan metabolism, as reported previously for antibiotic resistance (26) and drug metabolism (33) . Our finding that ber was dramatically, uniquely up-regulated upon exposure to its PINO substrate inspired the application of transcriptional-profiling (RNAseq) to probe the other three steps in the bacterial production of enterolignans. Together, these results emphasize the utility of RNAseq as a generalizable strategy 15 for linking genomic loci to metabolic activities (4, 29) , even in genetically intractable microorganisms. We anticipate that these two approaches could aid in efforts to gain a more systematic understanding of the full scope of chemical reactions that are enacted by the human microbiome.
Our results enabled the design of a simple culture-independent test for the capacity of the 20 gut microbiome to produce enterolignans, and thus impact host cellular pathways, on a lignan-rich diet. Continued refinement of this method and its functional validation would enable detecting and filling of gaps in key bacterial metabolic pathways through the selective introduction of specific strains to the gut microbiome. More broadly, these results set the stage for an in-depth analysis of the biochemistry of each of these enzymes (Fig. S3) WholeBiome, and Kaleido, and has active research funding from Medimmune. Data and materials availability: All data and code is available in the main text or supplemental materials, with the exception of RNA-sequencing data, which is available in NCBI's Sequence Read Archive, accession number SRP140684.
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